ATE50983T1 - Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen. - Google Patents

Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen.

Info

Publication number
ATE50983T1
ATE50983T1 AT86300037T AT86300037T ATE50983T1 AT E50983 T1 ATE50983 T1 AT E50983T1 AT 86300037 T AT86300037 T AT 86300037T AT 86300037 T AT86300037 T AT 86300037T AT E50983 T1 ATE50983 T1 AT E50983T1
Authority
AT
Austria
Prior art keywords
omega
dialkenoxy
ntri
dialkoxy
alk
Prior art date
Application number
AT86300037T
Other languages
English (en)
Inventor
Deborah Anne Eppstein
Gordon Henry Jones
Philips Louis Felgner
Richard Bolton Roman
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Application granted granted Critical
Publication of ATE50983T1 publication Critical patent/ATE50983T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
AT86300037T 1985-01-07 1986-01-06 Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen. ATE50983T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68940785A 1985-01-07 1985-01-07
EP86300037A EP0187702B1 (de) 1985-01-07 1986-01-06 Oberflächenaktive N-(omega, omega-1-Dialkoxy)- und N-(omega, omega-1-Dialkenoxy)-alk-1-yl-N,N,N-trisubstituierte Ammoniumverbindungen, deren Herstellung und sie enthaltende pharmazeutische Formulierungen

Publications (1)

Publication Number Publication Date
ATE50983T1 true ATE50983T1 (de) 1990-03-15

Family

ID=24768317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86300037T ATE50983T1 (de) 1985-01-07 1986-01-06 Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen.

Country Status (8)

Country Link
EP (1) EP0187702B1 (de)
JP (2) JPH0662517B2 (de)
AT (1) ATE50983T1 (de)
AU (1) AU594654B2 (de)
CA (1) CA1288774C (de)
DE (1) DE3669503D1 (de)
NZ (1) NZ214716A (de)
ZA (1) ZA8681B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
SE464448B (sv) * 1985-04-04 1991-04-29 Int Genetic Sciences Fusogen fosfolipidvesikel innehaallande ett kvaternaert ammoniumhydroxidsalt i membranet samt ett foerfarande foer dess framstaellning
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
ES2089226T3 (es) * 1990-09-06 1996-10-01 Johnson & Son Inc S C Procedimiento para estabilizar liposomas y composiciones que los contienen.
GB2250998A (en) * 1990-12-21 1992-06-24 Unilever Plc Cosmetic cleansing composition
JP3594962B2 (ja) * 1992-04-03 2004-12-02 コスモフェルム ベースローテン フェンノートシャップ アミノアルコールの選択的ｎ‐アシル化
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
JPH07308570A (ja) * 1994-05-16 1995-11-28 Hirotaka Hirata 界面活性物質を含む分子複合体
WO1997019675A2 (en) 1995-11-30 1997-06-05 Vical Incorporated Complex cationic lipids
DE19605175A1 (de) 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
US7384923B2 (en) 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
DE69717661T2 (de) 1996-09-13 2003-09-25 Lipoxen Technologies Ltd Liposomenzusammensetzung
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US7166745B1 (en) 1998-11-12 2007-01-23 Invitrogen Corporation Transfection reagents
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
EP1356820A1 (de) 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) DNA-Impfstoff kombiniert mit einen Apoptoneauslöser von Tumorzellen
JP2006273341A (ja) * 2005-03-28 2006-10-12 Toppan Printing Co Ltd 乾燥能力インジケーター機能付蓋
JP5072275B2 (ja) 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
AU2007314433B9 (en) 2006-10-06 2014-02-20 The Scripps Research Institute DNA composition for eliciting an immune response against tumor-associated macrophages
JP5080779B2 (ja) 2006-10-25 2012-11-21 テルモ株式会社 リポソーム製剤の製造方法
WO2009129387A2 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
EP2411519B1 (de) 2009-03-27 2015-07-22 Institut National de la Santé et de la Recherche Médicale Kanamycin-antisense-nucleinsäure zur behandlung von krebs
WO2011064790A1 (en) * 2009-11-30 2011-06-03 Avra Laboratories Pvt. Ltd A novel process for making aliskiren, its novel intermediates and certain novel compounds
EP3721943A1 (de) 2009-12-23 2020-10-14 Novartis AG Lipide, lipidzusammensetzungen und verfahren zu deren verwendung
US8889150B2 (en) 2010-03-17 2014-11-18 SOCPRA—Sciences et Génie, s.e.c. Bacterial vaccine components from Staphylococcus aureus and uses thereof
EP2567952A4 (de) 2010-04-28 2015-11-25 Kyowa Hakko Kirin Co Ltd Kationisches lipid
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
JP2013095755A (ja) 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
TWI594767B (zh) 2011-12-12 2017-08-11 協和醱酵麒麟有限公司 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
AU2012353463B2 (en) 2011-12-12 2017-08-24 Kyowa Hakko Kirin Co., Ltd. Lipid nanoparticles containing combinations of cationic lipids
CN107746852B (zh) 2012-05-04 2021-10-08 辉瑞公司 ***相关抗原及基于疫苗的免疫治疗疗法
US9913907B2 (en) 2012-07-16 2018-03-13 Kyowa Hakko Kirin Co., Ltd. RNAi pharmaceutical composition for suppressing expression of KRAS gene
CN106572974B (zh) 2014-07-15 2021-04-23 生命技术公司 用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
US10525138B2 (en) 2015-12-25 2020-01-07 Kyowa Hakko Kirin Co., Ltd. Compound as cationic lipid
PT3405212T (pt) 2016-01-19 2020-08-25 Pfizer Vacinas para o cancro
EP3529260A4 (de) 2016-10-21 2020-12-16 SOCPRA - Sciences et Génie s.e.c. Impfstoffkonstrukte und verwendungen davon gegen staphylococcus-infektionen
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
US20220185852A1 (en) 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567729A (en) * 1968-01-12 1971-03-02 Swift & Co Diquaternary ammonium halides

Also Published As

Publication number Publication date
ZA8681B (en) 1987-08-26
EP0187702B1 (de) 1990-03-14
NZ214716A (en) 1989-04-26
JPH0662517B2 (ja) 1994-08-17
JPH0770011A (ja) 1995-03-14
EP0187702A1 (de) 1986-07-16
AU594654B2 (en) 1990-03-15
JP2546623B2 (ja) 1996-10-23
CA1288774C (en) 1991-09-10
DE3669503D1 (de) 1990-04-19
JPS61161246A (ja) 1986-07-21
AU5185386A (en) 1986-07-17

Similar Documents

Publication Publication Date Title
ATE50983T1 (de) Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen.
FR2662162B1 (fr) Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DE19875024I2 (de) Amine Ihre verwendung und Herstellung
IL107426A0 (en) Heterocyclic compounds, processes for the preparation thereof, and pharmaceutical compositions containing the same
NO942953D0 (no) 11-benzaldoksimestradienderivater, fremgangsmåte for deres fremstilling smat legemddel inneholdende slike
AU565400B2 (en) 2-azaspiro(4 )-3-carboxylic acid derivatives
FR2526659B1 (fr) Medicaments immunomodulants a base de derives de l'acide phenylacetique
IT1228288B (it) Composti ad attivita' antiserotoninica
DK183789D0 (da) 2-alkyl-3-benzoylbenzofuraner og laegemidler indeholdende disse
AU576926B2 (en) Tetrazole derivatives
DE3752272D1 (de) Verwendung eines Thioesters zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Ischämie und von Reperfusion-Syndromen
NO167286C (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzotiazepin-derivater.
HUT40553A (en) Fungicides containing as active substance derivatives of imidasole and process for production of the active substance
IE41219L (en) Aralkyl esters of aminoalkanoic acids
PT83975B (pt) Processo para a preparacao de derivados de 5-aminoalquil-beta-carbolinas e de composicoes farmaceuticas que os contem
FR2694005B1 (fr) Nouvelles aminoalkylchromones, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
DK614989A (da) Indolderivater, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem
ATE56012T1 (de) Indolo-(6,5,4-cd)-indol derivate und verfahren zu deren herstellung.
FI933928A0 (fi) Heteroarenylpiperaziner, foerfarande foer framstaellning av dessa och anvaendning som laekemedel
DE3782619D1 (de) 1-hydroxyalkylxanthine, verfahren zu ihrer herstellung und sie enthaltende medikamente.
DE69631104D1 (de) 5,6,7,8-Tetrahydronaphto(2,3-b)furan- und indano(5,6-b)furan-amino-Verbindungen, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
AU4930797A (en) New ellipticine compounds, a process for their preparation and pharmaceutical compositions containing them
ATE87004T1 (de) Fluor enthaltende makrolid-verbindungen, pharmazeutische zusammensetzungen, welche diese enthalten und ihre verwendung fuer die herstellung von arzneimitteln.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time